Cellectis (CLLS) Income from Non-Controlling Interests (2015 - 2023)
Cellectis (CLLS) posted quarterly Income from Non-Controlling Interests of -$539.0 million for Q3 2025, up 17.33% year-over-year from -$459.4 million in Q3 2024, and down 182.67% quarter-over-quarter from $652.0 million in Q4 2024.
Analysis
Cellectis (CLLS) Income from Non-Controlling Interests (2015 - 2023) Analysis & Trends
Cellectis' Income from Non-Controlling Interests history runs 10 years deep, the most recent figure standing at -$539.0 million for Q3 2025.
- In Q3 2025, Income from Non-Controlling Interests rose 17.33% year-over-year to -$539.0 million; the TTM figure through Sep 2025 stood at -$539.0 million (up 17.33% YoY), while the FY2023 annual figure was -$7.4 million, up 6.46% from the prior year.
- Income from Non-Controlling Interests for Q3 2025 stood at -$539.0 million, down from $652.0 million in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $652.0 million in Q4 2024, with the low at -$652.0 million in Q3 2024.
- The 5-year median for Income from Non-Controlling Interests is -$2.8 million (2022), against an average of -$43.4 million.
- The sharpest annual moves came in 2022 and 2023: Income from Non-Controlling Interests soared 129.92% in 2022, then tumbled 1075.1% in 2023.
- Cellectis' Income from Non-Controlling Interests stood at -$3.1 million in 2021, then surged by 43.45% to -$1.7 million in 2022, then sank by 182.91% to -$4.9 million in 2023, then jumped by 13314.43% to $652.0 million in 2024, then slumped by 182.67% to -$539.0 million in 2025.
- Business Quant data shows CLLS's Income from Non-Controlling Interests at -$539.0 million in Q3 2025, $652.0 million in Q4 2024, and -$652.0 million in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | -4.93 Mn |
| Mar 31, 2023 | -2.45 Mn |
| Dec 31, 2022 | -1.74 Mn |
| Sep 30, 2022 | -2.80 Mn |
| Jun 30, 2022 | -506,000.00 |
| Mar 31, 2022 | -2.85 Mn |
| Dec 31, 2021 | -3.08 Mn |
| Sep 30, 2021 | -2.66 Mn |
| Jun 30, 2021 | -1.69 Mn |
| Mar 31, 2021 | -3.48 Mn |
| Dec 31, 2020 | 6.12 Mn |
| Sep 30, 2020 | -3.31 Mn |
| Jun 30, 2020 | -3.59 Mn |
| Mar 31, 2020 | -3.48 Mn |
| Dec 31, 2019 | -3.95 Mn |
| Sep 30, 2019 | -3.49 Mn |
| Jun 30, 2019 | -3.19 Mn |
| Mar 31, 2019 | -2.48 Mn |
| Dec 31, 2018 | -2.99 Mn |
| Sep 30, 2018 | -2.51 Mn |